

**MUSGROVE LEUKAEMIC GROUP SOMERSET**  
**Raising funds for the benefit of Patients in Somerset**

**UNAUDITED FINANCIAL STATEMENTS**

**FOR THE YEAR ENDED 29 FEBRUARY 2024**

**REGISTERED CHARITY NUMBER 1036580**

**MUSGROVE LEUKAEMIC GROUP SOMERSET**  
**Raising funds for the benefit of Patients in Somerset**

**TRUSTEES ANNUAL REPORT FOR THE YEAR ENDED 29 FEBRUARY 2024**

**REFERENCE AND ADMINISTRATION DETAILS**

Charity name:	Musgrove Leukaemic Group Somerset
Registered Charity number:	1036580
Charity's principal address:	16 Durleigh Road BRIDGWATER Somerset TA6 7HR
Trustees:	Mrs Patricia Reed (Chairperson) Miss Jane Allin (Secretary) Mrs Maureen Hudson Mrs Margaret Smith Mr Bernard Reed (Treasurer) Mrs Pat Cornish Mr David Edwards Mrs Margaret Edwards (resigned 12.7.23) Mrs Christine Regan (resigned 12.7.23)
Professional Advisors	
Bankers:	National Westminster Bank plc 26/27 Fore Street TAUNTON Somerset
Independent Examiner:	Moore Chartered Accountants 6th Floor Whitefriars Lewins Mead Bristol BS1 2NT

**STRUCTURE GOVERNANCE AND MANAGEMENT**

Musgrove Leukaemic Group Somerset is a registered charity and has been constituted as an unincorporated association governed by a formal constitution. A copy of the constitution may be obtained on application to the Secretary.

Trustees are elected at each Annual General Meeting but retiring Trustees are eligible for re-election. The Officers may hold office until retirement or by removal at an Annual General Meeting.

Co-opted Trustees may be appointed by the Committee at any time and generally have special knowledge or experience with leukaemia or related conditions. They may serve for such period as decided by the Committee or by their retirement.

**MUSGROVE LEUKAEMIC GROUP SOMERSET**  
**Raising funds for the benefit of Patients in Somerset**

**TRUSTEES ANNUAL REPORT FOR THE YEAR ENDED 29 FEBRUARY 2024**  
**(continued)**

**OBJECTIVES AND ACTIVITIES**

***The Charity's Objectives and activities for the Public Benefit***

The objects of the Group are to relieve persons suffering from Leukaemia and associated conditions by assisting and funding the treatments and welfare of such persons at Musgrove Park Hospital, Taunton Somerset or any other area authorised by the medical staff.

The Group carries out these objects by:

Sponsoring the medical staff that are considered key by the Somerset NHS Foundation Trust to maintaining Musgrove Park Hospital as a centre for the treatment of Leukaemia and other related diseases.

The grants made to nursing staff for training are in an aspect which when completed will enhance the experience of Leukaemia patients whilst receiving treatment for Leukaemia and other related diseases.

The purchase of equipment and furniture is made following recommendations from the medical staff with a view to improving the quality of the treatment and the emotional and physical well-being of both suffers and relatives.

***Charity Organisation and History***

The Musgrove Leukaemic Group Somerset was launched in 1978 and is run completely by unpaid volunteers who absorb all their own personal expenses. There are no paid Officers and overheads are kept to an absolute minimum thereby ensuring that most of the funds raised goes to the Haematology Unit at Musgrove Park Hospital, Taunton. The hospital has become a major centre in the South West for the diagnosis and treatment of leukaemia and related blood disorders.

In general the aims of the Group are as follows:

- i) To maintain Musgrove Park Hospital as a major centre for the diagnosis and treatment of leukaemia and related blood disorders by the most up-to-date techniques.
- ii) To keep the public informed on progress being made on the diagnosis and treatment of these diseases.

The Group meets regularly in Bridgwater and Taunton.

**MUSGROVE LEUKAEMIC GROUP SOMERSET**  
**Raising funds for the benefit of Patients in Somerset**

**TRUSTEES ANNUAL REPORT FOR THE YEAR ENDED 29 FEBRUARY 2024**  
**(continued)**

Policy is discussed at both Group and Committee meetings, but the Committee has the duty to manage the Group and the power to ultimately make executive decisions.

The Group has area representatives covering Somerset at Bridgwater, Burnham on Sea, Chard and Ilminster, Minehead, Taunton, and Wellington. The area representatives act as local contacts organising events and visiting various businesses, people or other organisations as required. In turn they report back to Group meetings on a regular basis.

## **ACHIEVEMENTS AND PERFORMANCE**

### ***Chairperson's Report***

It is pleasing to report that the Group has been able to recommence funding projects at Musgrove Park Hospital now that the restrictions imposed by the pandemic have been removed.

In the last financial year, we have purchased 6 new chemotherapy chairs for the Beacon Centre Day Unit and those previously purchased have been moved to the new unit at Wellington Hospital.

A Vital Signs monitor has been purchased which helps the medical team assess patient's fitness to undergo treatment.

A variety of equipment has been purchased for the Medusa room which is used by the Consultants to review patients' treatment. Sound proofing has been made to the Consulting Rooms in the Beacon Centre to ensure patient privacy.

A new Ambulatory Room has been established on Ward 9 and the Group have funded the equipment and furniture required.

The NHS Trust had one pool car. To ensure the haematology nurses had transport for the clinics at Bridgwater and Wellington the MLGS is sponsoring a pool car for that specific purpose. It is hoped in the future to provide a clinic at Williton.

The Group has received requests to fund additional equipment for the Ambulatory Room. The bathroom on Ward 9 is now unfit for purpose so funding is required to create a new wet room. It is hoped to restore the complementary therapy service on Ward 9 once a week.

Funds are held to support these projects and any other project that falls within our constitution to enable the Taunton and Somerset Foundation Trust to meet the needs of the patients.

I would like to thank the officers and committee members for their continued commitment through this difficult period.

**Tricia Reed**  
**Chairperson**

**MUSGROVE LEUKAEMIC GROUP SOMERSET**  
**Raising funds for the benefit of Patients in Somerset**

**TRUSTEES ANNUAL REPORT FOR THE YEAR ENDED 29 FEBRUARY 2024**  
**(continued)**

***Consultant's Report***

It has been a long time since our last report has been produced and inevitably there has been a number of updates and changes in the intervening 5 years. Not least the department, trust and the NHS has been through a pandemic which has significantly affected the health service and the charity group sector. In addition, the trust has undergone a merger with Yeovil hospital.

In the haematology department there have been a number of changes in personnel, in fact almost as many as the number of prime ministers we have had. Haematology consultants Simon Davis, Sarah Alford and our previous MLGS President Simon Bolam have all retired from clinical duties with myself taking over the President role of the MLGS. I am pleased to report that we have been able to successfully replace and recruit into these posts and we welcome our new consultant colleagues: Oliver Miles was previously working at Gloucester; Martin Best and Loredana Mihailescu were both trainees with us, so it is particularly nice to see them returning as consultants. We also welcome our newly funded roles of Hospital Speciality Trust doctors, Pratima Iyer and Desmond Maitland.

We have also managed to increase the number of CNSs to seven to assist with our increasing patient workload. With the trust merger the CNS roles at the two acute trusts have been consolidated to one body with all CNSs covering both sites. Emma Storey has managed a whole maternity leave in between these updates- many congratulations on the birth of her son.

We have also had a number of changes in our administration teams and not least the retirement of Shirley Bennett. Despite these changes over the years, we have continued to strive to improve the department and outcomes for patients.

As well the personnel the way of working in the department has also radically changed not least to cater for the inevitable increase in patients needing our care but also rather gloriously the new wave of drugs available which are revolutionizing the way we treat our patients. In this regard we do have to acknowledge the charity sector such as ours which help provide care to patients but also help develop these new drugs based on basic scientific and genomic research.

Therefore, I am pleased to report that despite the turbulent economic background the MLGS continues to strive thanks of the generosity of the public and of former patients who keep providing donations. We are in the happy position to report that we have a surplus which we have been able to use to good effect. We are funding a car loan deal which is used by our outreach nurses to provide chemotherapy and supportive medications in the community throughout Somerset and has been greatly welcomed by patients. This has effectively replaced the old 'Bumble' bus service- sadly a victim of the pandemic. We have also been managed to furnish our haematology day unit here at Musgrove Park with new state of the art specifically designed chairs. We have funded the development and furnishing of the ambulatory care service project adjacent to Ward 9. This results in patients who are receiving intensive chemotherapy to go home daily rather than a block of 5 weeks stuck in a ward room. In addition, funds have been released to fit ward 9 with further equipment including a new bladder scanner, cardiac monitoring hardware, a television for the ambulatory care room, hand grip patient assessment tool as well as further funds earmarked for bathroom conversions and more CAD pumps to deliver ambulatory chemotherapy. We also used

**MUSGROVE LEUKAEMIC GROUP SOMERSET**  
**Raising funds for the benefit of Patients in Somerset**

**TRUSTEES ANNUAL REPORT FOR THE YEAR ENDED 29 FEBRUARY 2024**  
**(continued)**

funding to purchase a dictation system to enable correspondence to be sent promptly to patients after clinic appointments, as we had a significant backlog of correspondence not able to be typed up and thus not getting to our GP colleagues and patients. We have also funded renovations to enable to make the clinic rooms soundproof.

Once again, the haematology department are overjoyed to have the support of the MLGS and we hope that we can use these funds wisely to improve the care and offer we can provide to the people of Somerset.

**Deepak Mannari**  
**Consultant Haematology**

**FINANCIAL REVIEW**

***Treasurers Report***

The total raised for the year ended 29<sup>th</sup> February 2024 amounted to £47,814.

The total expenditure for the year ended 29<sup>th</sup> February 2024 is £25,938.

The total raised since formation as at the 29<sup>th</sup> of February 2024 is £4,077,197.

The year ending February 2024 has seen a continued restricted fundraising activity. Unfortunately, this could become the norm going forward, therefore the continued support of our regular contributors, donors, and friends plus the dedicated work of the Trustees and Members is essential to enable the Group to continue to support projects at Musgrove Park Hospital.

The Trustees, members and volunteers absorb all their own expenses, so overheads are minimal and are currently under 1% of funds raised.

The Musgrove Leukaemic Group Somerset is in a sound financial position because of the large legacies received in the financial year ending 2022 that resulted in the Group's income for that year being £535,405. The Covid Pandemic prevented projects proceeding at the NHS Trust which has resulted in the retained funds held. It is not the Trustees intention to hold these monies in reserves.

Detailed accounts are attached for inspection.

**MUSGROVE LEUKAEMIC GROUP SOMERSET**  
**Raising funds for the benefit of Patients in Somerset**

**TRUSTEES ANNUAL REPORT FOR THE YEAR ENDED 29 FEBRUARY 2024**  
**(continued)**

**Reserves Policy**

Musgrove Leukaemic Group Somerset (MLGS) retains reserves, and this document explains our policy.

In defining this policy the Trustees have considered:

- 1) Income forecasts for future years taking into account the reliability of each source of income and the potential for securing new income from alternative sources.
- 2) Expenditure forecasts for future years.
- 3) The need to hold reserves should a medical breakthrough necessitate the urgent purchase of new equipment.
- 4) The need to hold reserves to meet our immediate commitments should income levels drastically fall.

The Group attempts to maintain reserves of approximately £200,000, which is represented by cash on short-term deposit and in the Group bank accounts. The present level of retained funds results from several legacies received in the financial year ending 2022, it is not the Trustees intention to hold these funds as reserves.

The Group believes it is prudent to keep this level of surplus to:

- 1) Ensure the Group can maintain its commitment to fund research salaries and consumables for year periods and to be able to so even if income levels should substantially fall for a period sufficient to allow alternative arrangements to be made.
- 2) To provide equipment on urgent request if the need should arise.
- 3) To act as a buffer against any unforeseen eventuality.

Our levels of reserves are constantly monitored and reviewed both at Group meetings and Committee meetings.

The present level of Reserves is considered appropriate to enable the Group to meet our commitments for the financial year ending 2025. The receipts received in 2022 has resulted in the Musgrove Leukaemic Group Somerset being in a strong financial position.

**Bernard Reed**  
**Hon. Treasurer.**

**MUSGROVE LEUKAEMIC GROUP SOMERSET**  
**Raising funds for the benefit of Patients in Somerset**

**TRUSTEES ANNUAL REPORT FOR THE YEAR ENDED 29 FEBRUARY 2024**  
**(continued)**

**Trustees' annual report**

The Musgrove Leukaemic Group Somerset (MLGS) was formed in April 1978 by a group of parents whose children were undergoing treatment for leukaemia. Due to the limited facilities at Musgrove Park Hospital they had to visit hospitals in Southampton and Bristol for treatment, placing severe strain on the families.

The present Trustees are a group of people continuing to fundraise to improve the facilities for leukaemia and lymphoma patients and their families in Somerset.

The funds raised by the MLGS are utilised to purchase equipment for the wards to improve the experience of patients whilst undergoing treatment.

The MLGS has now raised over £4 Million, 95% of which has/is being made available to Musgrove Park Hospitals' Haematology/Oncology and Children's Unit because all the Trustees and members services are voluntary.

The Trustees have approved several new projects to be completed in 2024 that will reduce the retained funds held.

The funds are raised by various means but principally from donations including legacies, collections, and other fundraising events.

Our aim is to continue to raise funds to improve the hospital experience for leukaemia and lymphoma patients.

**MUSGROVE LEUKAEMIC GROUP SOMERSET**  
**Raising funds for the benefit of Patients in Somerset**

**TRUSTEES ANNUAL REPORT FOR THE YEAR ENDED 29 FEBRUARY 2024**  
**(continued)**

**STATEMENT OF TRUSTEES RESPONSIBILITIES**

Charity law requires the trustees to prepare financial statements for each financial year which show a true and fair view of the state of affairs of the charity and its financial activities for that period. In preparing those financial statements, the trustees are required to


- Select suitable accounting policies and then apply them consistently;
- Make judgements and estimates that are reasonable and prudent;
- State whether applicable accounting standards and statements of recommended practice have been followed, subject to any departure disclosed and explained in the financial statements, and
- Prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in operational existence.

The Trustees are responsible for keeping proper accounting records which disclose with reasonable accuracy at any time the financial position of the charity and to enable them to ensure that the financial statements comply with the Charities Act 2011. They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

**DECLARATION**

The Trustees declare that they have approved the Trustees' Report.

Signed on behalf of the charity's trustees: 12th JUNE 2024



**Tricia Reed**  
**Chair**

**MUSGROVE LEUKAEMIC GROUP SOMERSET**  
**Raising funds for the benefit of Patients in Somerset**

**Independent Examiner's Report to the Trustees of Musgrove Leukaemic Group Somerset**

I report on the accounts of Musgrove Leukaemic Group Somerset for the year ended 29 February 2024 which are set out on pages 10 to 13.

**Respective responsibilities of trustees and examiner**

The charity's trustees are responsible for the preparation of the accounts. The charity's trustees consider that an audit is not required for this year under section 144 of the Charities Act 2011 (the Charities Act) and that an independent examination is needed.

It is my responsibility to:

- examine the accounts under section 145 of the Charities Act;
- to follow the procedures laid down in the general Directions given by the Charity Commissioners (under section 145 (5) (b) of the Charities Act); and
- to state whether particular matters have come to my attention.

**Basis of independent examiner's report**

My examination was carried out in accordance with the general Directions given by the Charity Commission. An examination includes a review of the accounting records kept by the charity and a comparison of the accounts presented with those records. It also includes consideration of any unusual items or disclosures in the accounts and seeking explanations from you as trustees concerning any such matters. The procedures undertaken do not provide all the evidence that would be required in an audit, and consequently no opinion is given as to whether the accounts present a 'true and fair' view and the report is limited to those matters set out in the statement below.

**Independent examiner's statement**

In connection with my examination, no matter has come to my attention:

- 1) which gives me reasonable cause to believe that in, any material respect, the requirements
  - to keep accounting records in accordance with section 130 of the Charities Act; and
  - to prepare accounts which accord with the accounting records and comply with the accounting requirements of the Charities Act have not been met: or
- 2) to which, in my opinion, attention should be drawn in order to enable a proper understanding of the accounts to be reached.



Mark Powell  
Moore  
6<sup>th</sup> Floor  
Whitefriars  
Lewins Mead  
Bristol  
BS1 2NT

Date: 20/6/2024

**MUSGROVE LEUKAEMIC GROUP SOMERSET**  
**Raising funds for the benefit of Patients in Somerset**

**STATEMENT OF FINANCIAL ACTIVITIES**  
**FOR THE YEAR ENDED 29 FEBRUARY 2024**

		Unrestricted Funds £	Restricted Funds £	Total Funds 2024 £	Total Funds 2023 £
<b>INCOME &amp; EXPENDITURE</b>					
<b>Incoming Resources</b>					
Donations, legacies and similar incoming resources:					
Donations		10,671	-	10,671	35,665
Fund Raising		8,242	-	8,242	6,398
Collections		1,558	-	1,558	1,388
Covenants & Gift Aid (including tax recovered)		2,405	-	2,405	3,299
Investment Income:					
Bank Interest		24,938	-	24,938	7,280
<b>TOTAL INCOMING RESOURCES</b>		<b>47,814</b>	<b>-</b>	<b>47,814</b>	<b>54,030</b>
<b>Resources Expended</b>					
	Note				
Direct Charitable Expenditure	2	24,743	-	24,743	1,145
Fund Raising and Publicity	3	209	-	209	-
Management and Administration	4	986	-	986	962
<b>TOTAL RESOURCES EXPENDED</b>		<b>25,938</b>	<b>-</b>	<b>25,938</b>	<b>2,107</b>
<b>NET (OUT)/INFLOW OF RESOURCES FOR THE YEAR AND MOVEMENT IN FUNDS</b>					
		21,876	-	21,876	51,923
Balance brought forward at 1 March 2023		889,393	-	889,393	837,470
<b>BALANCES CARRIED FORWARD AT 29 FEBRUARY 2024</b>		<b>911,269</b>	<b>-</b>	<b>911,269</b>	<b>889,393</b>

**MUSGROVE LEUKAEMIC GROUP SOMERSET**  
**Raising funds for the benefit of Patients in Somerset**

**BALANCE SHEET**  
**AS AT 29 FEBRUARY 2024**

	Note	2024 £	2023 £
<b>CURRENT ASSETS</b>			
Debtors	5	722	587
Short term deposits		750,000	505,943
Cash at bank and in hand		160,967	384,737
		<hr/>	<hr/>
		911,689	891,267
<b>CREDITORS:</b> Amounts falling due within one year	6	420	1,874
		<hr/>	<hr/>
<b>TOTAL NET ASSETS</b>		<b>911,269</b>	<b>889,393</b>
		<hr/>	<hr/>
Funded by:			
<b>UNRESTRICTED FUNDS</b>			
General Fund	7	911,269	889,393
		<hr/>	<hr/>

These accounts approved by the Trustees on. 12<sup>th</sup> JUNE 2024



**Bernard Reed**  
**Treasurer**  
**For and on behalf of the Trustees**



**Jane Allin**  
**Secretary**

**MUSGROVE LEUKAEMIC GROUP SOMERSET**  
**Raising funds for the benefit of Patients in Somerset**

**NOTES TO THE ACCOUNTS**  
**FOR THE YEAR ENDED 29 FEBRUARY 2024**

**1 ACCOUNTING POLICIES**

**a) Accounting basis and standards**

The financial statements have been prepared under the historical cost convention and in accordance with applicable accounting standards, the Charities SORP (FRS102) (Accounting and Reporting by Charities) and comply with the Charities (Accounts and Reports) Regulations 2008 issued under the Charities Act 2011.

**b) Voluntary Income**

Voluntary income is received from a number of sources, including donations, collections and other fund raising events. Such income is included in full in the income and expenditure account when received.

**c) Restricted and Unrestricted Funds**

Where appropriate, the accounts distinguish between restricted and unrestricted funds. The former are received from donors and are subject to restrictions on the purpose for which they may be used. Unrestricted funds are those where there are no externally imposed restrictions which the charity may use at its discretion to achieve its objectives.

In the opinion of the Officers the Charity does not operate any restricted funds.

**d) Short Term Deposits**

Short term deposits represent monies placed on deposit with National Westminster Bank Treasury Reserve Centre.

**e) Bank Interest**

Bank Interest is credited to the income and expenditure account when received.

**f) Covenants**

Covenants are credited to the income and expenditure account when received. Provision is made for recoverable income tax arising from the covenants.

**MUSGROVE LEUKAEMIC GROUP SOMERSET**  
**Raising funds for the benefit of Patients in Somerset**

**NOTES TO THE ACCOUNTS**  
**FOR THE YEAR ENDED 29 FEBRUARY 2024**  
**(Continued)**

**g) Taxation**

Musgrove Leukaemic Group Somerset is a registered charity and the results of its normal activities are not liable to corporation tax.

	Unrestricted Funds £	Restricted Funds £	Total Funds 2024 £	Total Funds 2023 £
<b>2 DIRECT CHARITABLE EXPENDITURE</b>				
(Amounts payable in furtherance of the Charities objects):				
Clinical unit grants	19,259	-	19,259	1,454
Complimentary medicine grants	-	-	-	(309)
Chemotherapy pool car grant	5,484	-	5,484	-
	<hr/>	<hr/>	<hr/>	<hr/>
	24,743	-	24,743	1,145
	<hr/>	<hr/>	<hr/>	<hr/>

The above grants were made in support of Musgrove Park Hospital in Taunton.

**3 FUND RAISING AND PUBLICITY**

Fund raising costs	-	-	-	-
Publications	209	-	209	-
	<hr/>	<hr/>	<hr/>	<hr/>
	209	-	209	-
	<hr/>	<hr/>	<hr/>	<hr/>

**MUSGROVE LEUKAEMIC GROUP SOMERSET**  
**Raising funds for the benefit of Patients in Somerset**

**NOTES TO THE ACCOUNTS**  
**FOR THE YEAR ENDED 29 FEBRUARY 2024**  
**(Continued)**

	Unrestricted Funds £	Restricted Funds £	Total Funds 2024 £	Total Funds 2023 £
<b>4 MANAGEMENT AND ADMINISTRATION OF CHARITY</b>				
Public liability insurance	566	-	566	542
Independent examiners fees	420	-	420	420
	<hr/> 986	<hr/> -	<hr/> 986	<hr/> 962
<b>5 DEBTORS</b>				
Income tax recoverable			722	587
			<hr/>	<hr/>
<b>6 CREDITORS: Amounts falling due within one year</b>				
Accountancy accrual			420	420
Clinical unit grants accrual			-	1,454
			<hr/> 420	<hr/> 1,874
			<hr/>	<hr/>
			<b>Balance 1.3.23 £</b>	<b>Net movement funds £</b>
<b>7 UNRESTRICTED FUNDS</b>				<b>Balance 29.2.24 £</b>
General Fund		889,393	21,876	911,269
		<hr/>	<hr/>	<hr/>